Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Overweight/Obese and/or T2DM Adolescents: A Meta-analysis Based on Randomized Controlled Trials

Dai M, Dai S, Gu L, Xiang Z, Xu A, Lu S, Yang Y, Zhou C

Journal of clinical research in pediatric endocrinology3 Jun 2024Cited by 11 (Europe PMC)

PMID38828884PMCIDPMC11590762DOI10.4274/jcrpe.galenos.2024.2024-1-5PepBankPUB-38828884

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. 2 results from people.

01HumanSystematic reviewEfficacy outcome
In adolescents with overweight/obesity and/or type 2 diabetes, liraglutide reduced body weight more than control (risk difference -2.31 kg, p=0.038).
In plain wordsIn adolescents, liraglutide reduced body weight more than control did.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
RD
−2.31 kg
liraglutide vs control
Source sentences
Summary
liraglutide (RD=-2.31 kg, p=0.038)
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.
Report a problemFND-3882888405
02HumanSystematic reviewEfficacy outcome
In adolescents with overweight/obesity and/or type 2 diabetes, liraglutide did not significantly reduce BMI versus control (risk difference -0.81 kg/m2, p=0.260).
In plain wordsIn adolescents, liraglutide did not clearly lower BMI compared with control.
Peptide
Liraglutide
Outcome
No significant changeBody mass index change
Study
n: not reported in source
Comparator
Control
Outcome group
Body weight · Metabolic and weight
Studied dose
Dose not stated
Measurements
RD
−0.81 kg/m2
liraglutide vs control
Source sentences
Summary
However, for the experimental group that received liraglutide, the BMI had a no significant reduction between the two groups (RD=-0.81 kg/m², p=0.260).
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.
Report a problemFND-3882888406

Studies that did not test the peptide alone4

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight/obesity and/or type 2 diabetes, pooled GLP-1 receptor agonists reduced HbA1c more than control (risk difference -0.34%, p<0.001).
In plain wordsIn adolescents, GLP-1 drugs as a group lowered HbA1c more than control did.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
RD
−0.34%
GLP-1RAs vs control
Source sentences
Summary
Results revealed that the GLP-1RAs group had a more significant reduction in glycosylated hemoglobin A1c (HbA1c; risk difference (RD)=-0.34%, p<0.001) than the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3882888401
04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight/obesity and/or type 2 diabetes, pooled GLP-1 receptor agonists did not significantly change fasting plasma glucose versus control (risk difference -2.07 mg/dL, p=0.065).
In plain wordsIn adolescents, GLP-1 drugs as a group did not clearly change fasting blood glucose compared with control.
Peptide
Liraglutide
Outcome
No significant changeFasting plasma glucose
Study
n: not reported in source
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Measurements
RD
−2.07 mg/dL
GLP-1RAs vs control
Source sentences
Summary
However, there was no difference in fasting plasma glucose [fasting plasma glucose (FPG); RD=-2.07 mg/dL, p=0.065] between the two groups.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3882888402
05HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight/obesity and/or type 2 diabetes, pooled GLP-1 receptor agonists reduced body weight more than control (risk difference -4.28 kg, p=0.002).
In plain wordsIn adolescents, GLP-1 drugs as a group reduced body weight more than control did.
Peptide
Liraglutide
Outcome
DecreaseBody weight change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
RD
−4.28 kg
GLP-1RAs vs control
Source sentences
Summary
The GLP-1RAs group had a more significant decline in body weight (RD=-4.28 kg, p=0.002) and body mass index (BMI) (RD=-1.63 kg/m², p=0.002) compared to the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3882888403
06HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome
In adolescents with overweight/obesity and/or type 2 diabetes, pooled GLP-1 receptor agonists reduced BMI more than control (risk difference -1.63 kg/m2, p=0.002).
In plain wordsIn adolescents, GLP-1 drugs as a group lowered BMI more than control did.
Peptide
Liraglutide
Outcome
DecreaseBody mass index change
Study
n: not reported in source
Comparator
Placebo
Outcome group
Body weight · Metabolic and weight
Measurements
RD
−1.63 kg/m2
GLP-1RAs vs control
Source sentences
Summary
The GLP-1RAs group had a more significant decline in body weight (RD=-4.28 kg, p=0.002) and body mass index (BMI) (RD=-1.63 kg/m², p=0.002) compared to the control group.
1 context sentence(design, population, supporting numbers)
Summary · context
PubMed, Embase, Web of Science, and Cochrane Library were searched for all randomized controlled trials (RCTs) up to August 2023 comparing GLP-1RAs with placebo in overweight/obese and/or T2DM adolescents and extracted relevant data for meta-analysis.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3882888404

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.